Info

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi). RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. The Company’s lead RNAi therapeutic program, ALN-RSV01, is for the treatment of human respiratory syncytial virus (RSV) infection. The Company has three RNAi therapeutic programs in pre-clinical development, ALN-PCS, ALN-VSP and ALN-HTT, focused on the treatment of hypercholesterolemia, liver cancer and Huntington’s disease (HD), respectively. Alnylam Pharmaceuticals has additional discovery programs for RNAi therapeutics for the treatment of a range of diseases.(Source: 10-K)